Company intelligence / Profile preview

Minneamrita Therapeutics LLC

Tampa, Florida, United Statesprofiles.biocentury.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Minnelide, the company's lead drug candidate, has shown evidence of clinical benefit in Phase I trials for refractory GI cancers. The drug is currently in Phase II for pancreatic cancer, Phase I/II for acute myeloid leukemia, and Phase I for gastric cancer. A Phase I trial in acute myeloid leukemia was terminated in October 2023 due to dose-limiting toxicity events.

Therapeutic areas: OncologyHematology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

triptolide

1 more asset in the full pipeline.

Request access →

Partnerships

University of Minnesota (license)Barts and The London NHS TrustQueen Mary University of LondonTranslational Genomics Research Institute

Beyond the preview

Go deeper on Minneamrita Therapeutics LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Minneamrita Therapeutics LLC.

Explore the full profile